ArticleFrontiers in immunology2023

Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.

Mary L Faber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.